ROVI — Laboratorios Farmaceuticos Rovi SA Share Price
0.000.00%
Last trade - 00:00- €4.26bn
- €4.31bn
- €829.51m
- 90
- 12
- 97
- 77
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.91 | ||
| PEG Ratio (f) | 6.01 | ||
| EPS Growth (f) | 4.32% | ||
| Dividend Yield (f) | 1.45% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.9 | ||
| Price to Tang. Book | 8.43 | ||
| Price to Free Cashflow | 73.41 | ||
| Price to Sales | 5.14 | ||
| EV to EBITDA | 17.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 36.71% | ||
| Return on Equity | 32.16% | ||
| Operating Margin | 26.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 381.31 | 419.96 | 648.68 | 817.7 | 829.51 | 815 | 898.85 | 22.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +105.21 | +62.29 | +139.45 | +33.94 | -14.25 | -4.13 | +26.45 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.
Directors
- Juan Lopez-Belmonte Lopez CHM
- Juan Lopez-Belmonte Encina CEO
- Javier Lopez-Belmonte Encina VCH
- Ivan Jorge Lopez-Belmonte Encina VCH
- Beatriz Alcalde DSL
- M. Rosario Perez DMK
- Francisco Javier Angulo Garcia DHR
- Pedro Carretero Trillo OTH
- Miguel Angel Castillo San Roman OTH
- Mercedes Benitez Del Castillo Sanchez OTH
- Fernando Garijo OTH
- Ibon Gutierro Aduriz OTH
- Miguel Angel Ortega Sanchez OTH
- Marcos Pena Pinto LED
- Fatima Benez Garcia IND
- Jose Fernando de Almansa Moreno-Barreda IND (72)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 21st, 1946
- Public Since
- October 26th, 2007
- No. of Employees
- 2,111
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Madrid Stock Exchange
- Shares in Issue
- 51,820,146
- Address
- C/ Julian Camarillo, 35, MADRID, 28037
- Web
- https://www.rovi.es/
- Phone
- +34 913756230
- Contact
- Marta Campos
- Auditors
- KPMG Auditores, SL
Upcoming Events for ROVI
Q4 2024 Laboratorios Farmaceuticos ROVI SA Earnings Release
Q2 2024 Laboratorios Farmaceuticos ROVI SA Earnings Release
Similar to ROVI
1nkemia IUCT SA
Madrid Stock Exchange
Almirall SA
Madrid Stock Exchange
Faes Farma SA
Madrid Stock Exchange
Grifols SA
Madrid Stock Exchange
Labiana Health SA
Madrid Stock Exchange
FAQ
What is the Laboratorios Farmaceuticos Rovi SA share price?
As of Today at 19:12 UTC, shares in Laboratorios Farmaceuticos Rovi SA are trading at €82.25. This share price information is delayed by 15 minutes.
How has the Laboratorios Farmaceuticos Rovi SA share price performed this year?
Shares in Laboratorios Farmaceuticos Rovi SA last closed at €82.25 and the price had moved by +101.49% over the past 365 days. In terms of relative price strength the Laboratorios Farmaceuticos Rovi SA share price has outperformed the FTSE Global All Cap Index by +85.86% over the past year.
What are the analyst and broker recommendations for Laboratorios Farmaceuticos Rovi SA?
The overall consensus recommendation for Laboratorios Farmaceuticos Rovi SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Laboratorios Farmaceuticos Rovi SA dividend yield?
The Laboratorios Farmaceuticos Rovi SA dividend yield is 1.34% based on the trailing twelve month period.
Does Laboratorios Farmaceuticos Rovi SA pay a dividend?
Last year, Laboratorios Farmaceuticos Rovi SA paid a total dividend of €1.10, and it currently has a trailing dividend yield of 1.34%. We do not have any data on when Laboratorios Farmaceuticos Rovi SA is to next pay dividends.
When does Laboratorios Farmaceuticos Rovi SA next pay dividends?
We do not have data on when Laboratorios Farmaceuticos Rovi SA is to next pay dividends. The historic dividend yield on Laboratorios Farmaceuticos Rovi SA shares is currently 1.34%.
How do I buy Laboratorios Farmaceuticos Rovi SA shares?
To buy shares in Laboratorios Farmaceuticos Rovi SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Laboratorios Farmaceuticos Rovi SA?
As of the previous close price of €82.25, shares in Laboratorios Farmaceuticos Rovi SA had a market capitalisation of €4.26bn.
Where are Laboratorios Farmaceuticos Rovi SA shares listed?
Here are the trading details for Laboratorios Farmaceuticos Rovi SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: ROVI
What kind of share is Laboratorios Farmaceuticos Rovi SA?
Based on an overall assessment of its quality, value and momentum Laboratorios Farmaceuticos Rovi SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Laboratorios Farmaceuticos Rovi SA share price forecast for 2024?
The analyst consensus target price for shares in Laboratorios Farmaceuticos Rovi SA is €75.40. That is 8.33% below the last closing price of €82.25.
Analysts covering Laboratorios Farmaceuticos Rovi SA currently have a consensus Earnings Per Share (EPS) forecast of €3.07 for the next financial year.
What is the trend in the Laboratorios Farmaceuticos Rovi SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laboratorios Farmaceuticos Rovi SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +38.11%.
As of the last closing price of €82.25, shares in Laboratorios Farmaceuticos Rovi SA were trading +42.55% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Laboratorios Farmaceuticos Rovi SA PE Ratio?
The Laboratorios Farmaceuticos Rovi SA PE ratio based on its reported earnings over the past 12 months is 24.91. The shares last closed at €82.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Laboratorios Farmaceuticos Rovi SA?
Laboratorios Farmaceuticos Rovi SA's management team is headed by:
- Juan Lopez-Belmonte Lopez - CHM
- Juan Lopez-Belmonte Encina - CEO
- Javier Lopez-Belmonte Encina - VCH
- Ivan Jorge Lopez-Belmonte Encina - VCH
- Beatriz Alcalde - DSL
- M. Rosario Perez - DMK
- Francisco Javier Angulo Garcia - DHR
- Pedro Carretero Trillo - OTH
- Miguel Angel Castillo San Roman - OTH
- Mercedes Benitez Del Castillo Sanchez - OTH
- Fernando Garijo - OTH
- Ibon Gutierro Aduriz - OTH
- Miguel Angel Ortega Sanchez - OTH
- Marcos Pena Pinto - LED
- Fatima Benez Garcia - IND
- Jose Fernando de Almansa Moreno-Barreda - IND